|
"hsu c"的相關文件
顯示項目 761-785 / 881 (共36頁)
<< < 26 27 28 29 30 31 32 33 34 35 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2012 |
EXPLORING THE ANTI-TUMOR EFFICACY OF COMBINATION THERAPY WITH INHIBITORS TARGETING THE INSULIN-LIKE GROWTH FACTOR (IGF) AND PI3K/AKT/MTOR SIGNALING PATHWAYS FOR HEPATOCELLULAR CARCINOMA (HCC)
|
Ou, D. -L.; Hsu, C.; Lee, B. -S.; Chang, Y. -C.; Cheng, Y. -C.; Cheng, A. -L.; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2012 |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao, Y-Y; Lu, L-C; Lin, Z-Z; Hsu, C.; Shen, Y-C; Hsu, C-H; Cheng, A-L; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿; 呂理駿 |
| 國立臺灣大學 |
2012 |
THE ROLES OF GROWTH ARREST DNA DAMAGE-INDUCIBLE GENE 45 Gamma (GADD45 Gamma) EXPRESSION IN SORAFENIB-INDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA (HCC) CELLS
|
Hsu, C.; Ou, D. -L.; Shiau, C. -W.; Fan, H. -H.; Liao, S. -C.; Lin, Y. -Y.; Hsu, C. -H.; Cheng, A. -L.; 林育誼; 鄭安理; 徐志宏; 許駿; 歐大諒 |
| 國立臺灣大學 |
2012 |
THE FIRST-TWO LINES OF CHEMOTHERAPY FOR DE NOVO METASTATIC BREAST CANCER: EFFICACY STUDY BETWEEN ANTHRACYCLINES AND NON-ANTHRACYCLINES
|
Chen, W. -W.; Chang, D. -Y.; Lin, C. -H.; Hsu, C.; Cheng, A. -L.; Lu, Y. -S.; 陳偉武; 盧彥伸; 鄭安理; 許駿; 張端瑩; 林璟宏 |
| 國立臺灣大學 |
2012 |
Changes of Pulmonary Fluorodeoxyglucose Uptake After Neoadjuvant Concurrent Chemoradiation in Predicting Postoperative Pulmonary Complications for Patients With Esophageal Cancer
|
Hsu, F.; Cheng, J.; Lee, J.; Huang, P.; Hsu, C.; Lin, C.; Tsai, Y.; Tzen, K.; Yen, R.; 曾凱元; 成佳憲; 顏若芳; 蔡育傑; 許駿; 李章銘; 黃培銘; 許峰銘 |
| 國立臺灣大學 |
2012 |
CHLORHEXIDINE FOR THE PREVENTION OF BLOODSTREAM INFECTION (BSI) ASSOCIATED WITH PERMANENTLY IMPLANTABLE VENOUS PORTS (PORT-A) IN SOLID CANCER PATIENTS: A PROSPECTIVE COHORT STUDY
|
Kao, H.; Chen, I.; Chang, S.; Hong, M.; Chien, S.; Hu, F.; Hsu, C.; Yeh, K.; 許駿 |
| 國立臺灣大學 |
2012 |
CYCLIN E1 SUPPRESSION CONTRIBUTES TO SORAFENIB-INDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA (HCC)
|
Hsu, C.; Ou, D.; Cheng, Y.; Lin, Y.; Chang, Y.; Yeh, K.; Cheng, A.; 鄭安理; 許駿; 歐大諒 |
| 臺大學術典藏 |
2012 |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Hsu C.; Hu F.-C.; YU-YUN SHAO; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2012 |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Cheng A.-L.;Yen-Shen Lu;Hsu C;Huang S.-M;Yang S.-H;Chen T.-J;Shau W.-Y;Lin C.-H;Kuo Y.-H; Kuo Y.-H; Lin C.-H; Shau W.-Y; Chen T.-J; Yang S.-H; Huang S.-M; Hsu C; YEN-SHEN LU; Cheng A.-L. |
| 國家衛生研究院 |
2011-12 |
Increased expression of 14-3-3beta promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Liu, TA;Jan, YJ;Ko, BS;Chen, SC;Liang, SM;Hung, YL;Hsu, C;Shen, TL;Lee, YM;Chen, PF;Wang, J;Shyue, SK;Liou, JY |
| 國家衛生研究院 |
2011-04 |
Overexpression of 14-3-3 epsilon predicts tumour metastasis and poor survival in hepatocellular carcinoma
|
Ko, BS;Chang, TC;Hsu, C;Chen, YC;Shen, TL;Chen, SC;Wang, J;Wu, KK;Jan, YJ;Liou, JY |
| 國家衛生研究院 |
2011-02 |
Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma
|
Lin, C;Hsu, C;Cheng, JC;Yen, C;Shiah, H;Lee, J;Wang, H;Yeh, K;Cheng, A;Lee, Y |
| 國家衛生研究院 |
2011-02 |
Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers
|
Yeh, K;Shen, Y;Li, C;Yen, C;Hsu, C;Lin, Z;Chen, L;Su, W;Chao, Y;Cheng, A |
| 國立政治大學 |
2011 |
The design of the mobile service: Fit between mobility and customer variability
|
Chang, Hsin-Lu;Lin, J.-R.;Wang, K.;Hsu, C.;Tai, J.C.-F.; 張欣綠 |
| 臺大學術典藏 |
2011 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Yu C.-W.; Hsu C.; Hu F.-C.; CHIH-HUNG HSU; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Shen Y.-C.; Hsu C.-Y.; Hsu C.-Y. ;Shen Y.-C. ;Yu C.-W. ;Hsu C. ;Hu F.-C. ;Chih-Hung Hsu ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F. |
| 臺大學術典藏 |
2011 |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Cheng A.L.; YEN-SHEN LU; Kuo W.H; Chen I.C; Lin C.H; Huang C.S; Lien H.C; Hsu C; Chen I.C;Lin C.H;Huang C.S;Lien H.C;Hsu C;Kuo W.H;Yen-Shen Lu;Cheng A.L. |
| 臺大學術典藏 |
2011 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Chen B.-B.; Hsu C.-H.; Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Wei S.-Y.; Cheng A.-L.; TIFFANY TING-FANG SHIH |
| 國家衛生研究院 |
2010-01-30 |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B
|
Ko, BS;Chang, TC;Chen, CH;Liu, CC;Kuo, CC;Hsu, C;Shen, YC;Shen, TL;Golubovskaya, VM;Chang, CC;Shyue, SK;Liou, JY |
| 國家衛生研究院 |
2010 |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
|
Shen, YC;Hsu, C;Chen, LT;Cheng, CC;Hu, FC;Cheng, AL |
| 國家衛生研究院 |
2009-10 |
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Jan, YJ;Ko, BS;Hsu, C;Chang, TC;Chen, SC;Wang, J;Liou, JY |
| 國家衛生研究院 |
2009-09-15 |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou, DL;Shen, YC;Liang, JD;Liou, JY;Yu, SL;Fan, HH;Wang, DS;Lu, YS;Hsu, C;Cheng, AL |
| 國家衛生研究院 |
2009-05-20 |
Helicobacter pylori-independent MALT lymphoma patients responsive to thalidomide-the molecular mechanism and the clinical application
|
Kuo, S;Chen, L;Wu, M;Hsu, C;Lin, C;Hsu, P;Yeh, K;Tzeng, Y;Cheng, A |
| 國家衛生研究院 |
2009-04-24 |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen, KF;Yeh, PY;Hsu, C;Hsu, CH;Lu, YS;Hsieh, HP;Chen, PJ;Cheng, AL |
| 國立臺灣大學 |
2009-04 |
Frame Misalignment: Interpreting the Implementation of Information Systems Security Certification in an Organization
|
Hsu, C. |
| 國立臺灣大學 |
2009-03 |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
|
Lin, ZZ; Hsu, HC; Hsu, CH; Yeh, PY; Huang, CY; Huang, YF; Chen, TJ; Kuo, SH; Hsu, C; Hu, FC; Jeng, YM; Chung, Y; Cheng, AL. |
顯示項目 761-785 / 881 (共36頁)
<< < 26 27 28 29 30 31 32 33 34 35 > >>
每頁顯示[10|25|50]項目
|
